Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Nuformix (NFX) Share Price

Price 0.23p on 07-10-2025 at 18:50:08
Change 0.035p 17.95%
Buy 0.25p
Sell 0.21p
Last Trade: Unknown 50,000.00 at 0.23p
Day's Volume: 111,090,950
Last Close: 0.23p
Open: 0.195p
ISIN: GB00BYW79Y38
Day's Range 0.175p - 0.23p
52wk Range: 0.04p - 0.36p
Market Capitalisation: £3.90m
VWAP: 0.203064p
Shares in Issue: 1.70b

Nuformix (NFX) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Unknown* 50,000 0.23p Ordinary
16:27:23 - 07-Oct-25
Unknown* 150,000 0.23p Ordinary
16:18:01 - 07-Oct-25
Sell* 50,000 0.21p Ordinary
16:16:34 - 07-Oct-25
Unknown* 40,626 0.23p Ordinary
16:16:00 - 07-Oct-25
Sell* 220,000 0.212p Ordinary
16:15:36 - 07-Oct-25
Buy* 398,009 0.232p Ordinary
16:14:28 - 07-Oct-25
Sell* 79,858 0.2124p Ordinary
16:14:02 - 07-Oct-25
Sell* 853,338 0.21782p Ordinary
16:10:57 - 07-Oct-25
Sell* 50 0.21p Ordinary
16:08:25 - 07-Oct-25
Buy* 500,000 0.2323p Ordinary
16:06:11 - 07-Oct-25
See more Nuformix trades

Nuformix (NFX) Share Price History

Time period:
to
Date Open High Low Close Volume
7th Oct 2025 (Tue) 0.195 0.23 0.175 0.23 111,090,950
6th Oct 2025 (Mon) 0.20 0.23 0.19 0.195 87,360,448
3rd Oct 2025 (Fri) 0.24 0.24 0.24 0.24 103,229,334
2nd Oct 2025 (Thu) 0.30 0.36 0.22 0.235 290,314,324
1st Oct 2025 (Wed) 0.231 0.36 0.231 0.30 303,126,410
30th Sep 2025 (Tue) 0.19 0.275 0.19 0.235 251,489,218
29th Sep 2025 (Mon) 0.145 0.2075 0.145 0.19 245,025,163
26th Sep 2025 (Fri) 0.1175 0.165 0.1175 0.145 154,534,245
25th Sep 2025 (Thu) 0.105 0.13 0.105 0.13 245,601,705
24th Sep 2025 (Wed) 0.105 0.105 0.105 0.105 13,858,584
23rd Sep 2025 (Tue) 0.11 0.11 0.105 0.105 1,920,237
22nd Sep 2025 (Mon) 0.11 0.11 0.11 0.11 6,034,736
19th Sep 2025 (Fri) 0.11 0.11 0.11 0.11 8,311,034
18th Sep 2025 (Thu) 0.11 0.11 0.11 0.11 1,510,750
17th Sep 2025 (Wed) 0.115 0.11 0.11 0.11 19,581,982
16th Sep 2025 (Tue) 0.1175 0.12 0.115 0.115 32,465,782
15th Sep 2025 (Mon) 0.115 0.12 0.115 0.1175 43,087,116
12th Sep 2025 (Fri) 0.125 0.125 0.115 0.115 73,138,606
11th Sep 2025 (Thu) 0.125 0.15 0.115 0.125 207,207,822
10th Sep 2025 (Wed) 0.095 0.125 0.095 0.125 199,691,900
9th Sep 2025 (Tue) 0.095 0.095 0.095 0.095 11,619,972
8th Sep 2025 (Mon) 0.105 0.105 0.095 0.095 29,909,293
See more Nuformix price history

Nuformix (NFX) Regulatory News

Date Source Headline
25th Sep 2025 7:00 am RNS-R European Respiratory Society Congress Attendance
11th Aug 2025 7:00 am RNS US FDA ODD Application Submitted for NXP002
30th May 2025 2:24 pm RNS Total Voting Rights
29th May 2025 7:00 am RNS Confirmation of European ODD for NXP002
23rd May 2025 1:08 pm RNS Publication of a Prospectus
22nd May 2025 7:00 am RNS £210,000 Placing
19th May 2025 7:00 am RNS-R Attendance at American Thoracic Society Congress
2nd May 2025 7:00 am RNS Half-year Report
30th Apr 2025 7:00 am RNS Confirmation of European Orphan Drug Designation
29th Apr 2025 7:00 am RNS Change of Registered Office and Company Secretary
See more Nuformix regulatory news

Nuformix (NFX) Share News

IN BRIEF: Nuformix submits FDA drug designation application for NXP002

11th Aug 2025 12:11

Nuformix PLC - London-based developer of treatments for fibrosis and oncology - Submits US Food & Drug Administration orphan drug designation application for the NXP002 programme in idiopathic pulmonary fibrosis. If the orphan drug designation is granted, Nuformix may be eligible for some benefits, like tax credits for clinical trials or qualified clinical testing costs. Read More

Nuformix shares fall despite EU orphan drug status for lead treatment

29th May 2025 18:21

(Alliance News) - Nuformix PLC on Thursday said its lead programme, NXP002, has been granted orphan drug designation by the European Medicines Agency for the treatment of idiopathic pulmonary fibrosis. Read More

Nuformix interim loss widens as focused on advancing assets

2nd May 2025 12:19

(Alliance News) - Nuformix PLC on Friday said it has continued to "advance and exploit" assets in its portfolio, two days after noting a positive opinion from an EU committee for NXP002. Read More

Nuformix finds positive data for NXP002 in lung fibrosis study

9th Apr 2025 16:29

(Alliance News) - Nuformix PLC on Wednesday said fresh analysis of lung tissue from patients with idiopathic pulmonary fibrosis and autoimmune-related interstitial lung disease showed "positive" results for its lead asset NXP002, supporting its potential in treating a wider range of fibrotic conditions. Read More

UK shareholder meetings calendar - next 7 days

13th Mar 2025 14:41

Read More

See more Nuformix news
FTSE 100 Latest
Value9,483.58
Change4.44

Login to your account

Forgot Password?

Not Registered